Home Intro

Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many severe inflammatory, allergic and autoimmune diseases. By targeting a core pathological driver of these diseases, we have designed barzolvolimab with the potential to be a best-in-class treatment option and improve the lives of patients.

Learn More

Our Science

Driven by our deep and longstanding experience developing antibody-based immunotherapies, Celldex’s proprietary antibody programs and technologies are supported by robust in-house capabilities, enabling the optimized discovery and development of innovative scientific programs.

Learn More

Image of people watching a presentation at a conference

Events & Presentations

View our upcoming events and recent presentations

Learn More
Image of scientist's hands in lab

Clinical Trials

For information on Celldex’s ongoing clinical studies, including information about how to enroll, please click here:

Learn More
image of scientist in lab


Celldex is always looking for passionate and talented individuals to join our team

Learn More